To assess the clinical implication of complete and incomplete metastasectomy in the patients having metachronous metastatic RCC (mRCC).
INTRODUCTION AND OBJECTIVES:
To assess the clinical implication of complete and incomplete metastasectomy in the patients having metachronous metastatic RCC (mRCC).
METHODS: We retrospectively reviewed metachronous mRCC treated at our institute between January 2005 and December 2015. Metachronous mRCC was defined as those diagnosed of metastatic disease >3month after initial nephrectomy. Patients were classified into three groups; A. targeted therapy for metachronouc mRCC without additional surgical treatment. B. complete metastasectomy and adjuvant targeted therapy. C. incomplete metastasectomy and adjuvant targeted therapy. Cox proportional hazard regression analysis was performed to determine if complete and incomplete metastasectomy prolongs overall survival (OS) for the metachronous mRCC.
RESULTS: Total of 101 patients were enrolled and followed up for 41.9 months in this study. 22 patients (21.8%) underwent complete metastasectomy, while 17 patients (16.8%) underwent incomplete metastasectomy. Most commonly performed metastasectomy was lung wedge resection (n¼14, 13.9%), followed by bone excision (n¼9, 8.9%), and local recur resection (n¼6, 5.9%). Overall, incomplete metastasectomy and complete metastasectomy prolonged OS (HR 0.608, 0.318, p¼0.042, respectively). Complete and incomplete lung wedge resection both prolonged overall survival significantly (p<0.05). Metastasectomy for bone and retroperitoneum recurred mass both did not show survival benefit (p¼0.590 and 0.133, respectively). For the other metastasis, we labeled them as soft tissue metastasis, and soft tissue metastasectomy prolonged OS (p¼0.036). Incomplete metastasectomy for soft tissue prolonged OS (p¼0.016) CONCLUSIONS: Metastasectomy could prolong OS in metachronous mRCC. Except for metastasectomy for bone and retroperitoneum recurred mass, incomplete metastasectomy also could play a role as OS prolongation. METHODS: We conducted a retrospective analysis on a cohort of 62 consecutive patients presenting with local recurrence after primary surgical treatment for RC at two academic institutions. In 25 cases (40.3%), patients presenting concomitant visceral and/or bone metastases were excluded. LR was defined as the presence of a pathologically confirmed recurrence of RC in the soft/tissue renal fossa after radical (RN) or at the level of the resection bed after partial nephrectomy (PN), respectively. All patients were treated with the complete surgical resection of the LR. Kaplan-Meier analysis was applied to assess rates of systemic progression (SP; defined as the evidence of distant metastases during the follow-up), disease-free survival (DFS; defined as the absence of either distant or local recurrence) and cancer specific mortality (CSM) after surgical resection of LR RESULTS: Overall, 37 patients had exclusive LR (59.6%). Of those, 21 (55.6%) vs. 16 (44.4%) patients were diagnosed with an LR after RN vs. PN, respectively. Median [mean (Q1-Q3)] time to LR was 18 [29.9 (8-42) ] months after RN/PN. At initial treatment (PN or RN), pathologic T stage (pT) was pT1, pT2, pT3 and pT4 in 14 (38.2%) 8 (18.9%), 14 (38.2%) and 1 (2.9%) patients. Fuhrman grade resulted low (1-2) vs. high (3-4) in 21 (59.4%) vs. 16 (40.7%) patients. At LR diagnosis, 28 (75.7%) patients were treated with LR resection only, while 9 (24.3%) received also systemic targeted therapy after LR resection. At 1 and 3 years after LR surgery, SP rates were 20% and 45% vs. 7% and 23% in RN vs. PN cases, respectively. Overall, at 1, 3 and 5 years after LR surgery, DFS was 93%, 85% and 67%. CSM resulted 10%, 20% and 25%, respectively. There was no significant difference in terms of SP, DFS and CSM between patients surgically treated for LR after RN or PN (all p>0.05).
CONCLUSIONS: Despite a surgical treatment of LR after either PN or RN, a systemic progression can be expected. However, given the encouraging results in terms of DFS and CSM, such management could be justified in clinical practice.
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